Skip to main content
ROIV
NASDAQ Life Sciences

Roivant Reports Unexpected Q4 Profit, $4.3B Cash, and Breakthrough Therapy Designation for Brepocitinib

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$29.11
Mkt Cap
$20.19B
52W Low
$10.58
52W High
$30.33
52W Position info
175% above low
Off High info
4.0% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $10.58.

Summary

Roivant Sciences reported an unexpected Q4 net profit, a strong $4.3 billion cash position, and received Breakthrough Therapy Designation for its brepocitinib program in cutaneous sarcoidosis.


Key Events · Earnings and Guidance · ROIV

  • Unexpected Q4 Profit Reported

    Roivant reported income from continuing operations, net of tax, of $355.7 million for the fourth quarter, significantly beating analyst expectations and marking a substantial turnaround from a loss of $252.4 million in the prior year quarter.

  • Strong Cash Position and Runway

    The company ended the fiscal year with $4.3 billion in consolidated cash, cash equivalents, and marketable securities, supporting a cash runway into profitability.

  • Breakthrough Therapy Designation for Brepocitinib

    The FDA granted Breakthrough Therapy Designation for brepocitinib in cutaneous sarcoidosis based on positive Phase 2 data, potentially accelerating its development and regulatory pathway.

  • Positive Clinical Data for IMVT-1402

    IMVT-1402 showed clinically meaningful response rates in its open-label trial for difficult-to-treat rheumatoid arthritis, with further updates expected in the second half of 2026.


Analysis · ROIV · Life Sciences

Roivant Sciences reported an unexpected net profit for the fourth quarter, a significant turnaround from previous losses, driven in part by the recognition of a substantial litigation settlement gain. The company also highlighted a robust cash position of $4.3 billion, which extends its cash runway into profitability. Furthermore, a key pipeline asset, brepocitinib, received Breakthrough Therapy Designation from the FDA for cutaneous sarcoidosis, which can accelerate its development and regulatory review. These combined factors provide a strong positive outlook for the company's financial stability and pipeline progression.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ROIV was trading at $29.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.2B. The 52-week trading range was $10.58 to $30.33. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $38.68 info
Change: -$2.69 (-7%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $38.68 info
Change: -$2.32 (-6%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $38.68 info
Change: -$1.71 (-4%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $38.68 info
Change: +$2.48 (+7%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $38.68 info
Change: +$2.08 (+6%) info
Market Cap: $28.008B info